{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:23:41Z","timestamp":1760747021079,"version":"build-2065373602"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"DOI":"10.7759\/cureus.94790","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:51:10Z","timestamp":1760709070000},"source":"Crossref","is-referenced-by-count":0,"title":["IgG4-Related Disease: A Case Series Highlighting Diverse Clinical Manifestations and Treatment Outcomes"],"prefix":"10.7759","author":[{"given":"Thanda","family":"Aung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin","family":"Eblen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A","family":"Fishbein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1104650","article-title":"IgG4-related disease","volume":"366","author":"Stone JH","year":"2012","unstructured":"Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012, 366:539-51. 10.1056\/NEJMra1104650","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-003-1175-y","article-title":"A new clinicopathological entity of IgG4-related autoimmune disease","volume":"38","author":"Kamisawa T","year":"2003","unstructured":"Kamisawa T, Funata N, Hayashi Y, et al.. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003, 38:982-4. 10.1007\/s00535-003-1175-y","journal-title":"J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-011-0508-6","article-title":"A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details","volume":"22","author":"Umehara H","year":"2012","unstructured":"Umehara H, Okazaki K, Masaki Y, et al.. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012, 22:1-14. 10.1007\/s10165-011-0508-6","journal-title":"Mod Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande V","year":"2012","unstructured":"Deshpande V, Zen Y, Chan JK, et al.. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012, 25:1181-92. 10.1038\/modpathol.2012.72","journal-title":"Mod Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182431ef6","article-title":"Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients","volume":"91","author":"Khosroshahi A","year":"2012","unstructured":"Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012, 91:57-66. 10.1097\/MD.0b013e3182431ef6","journal-title":"Medicine (Baltimore)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers MN","year":"2015","unstructured":"Carruthers MN, Topazian MD, Khosroshahi A, et al.. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015, 74:1171-7. 10.1136\/annrheumdis-2014-206605","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12641","article-title":"Immunology of IgG4-related disease","volume":"181","author":"Della-Torre E","year":"2015","unstructured":"Della-Torre E, Lanzillotta M, Doglioni C. Immunology of IgG4-related disease. Clin Exp Immunol. 2015, 181:191-206. 10.1111\/cei.12641","journal-title":"Clin Exp Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205233","article-title":"Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations","volume":"74","author":"Wallace ZS","year":"2015","unstructured":"Wallace ZS, Mattoo H, Carruthers M, et al.. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015, 74:190-5. 10.1136\/annrheumdis-2014-205233","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216561","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"79","author":"Wallace ZS","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, et al.. The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020, 79:77-87. 10.1136\/annrheumdis-2019-216561","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease","volume":"392","author":"Stone JH","year":"2025","unstructured":"Stone JH, Khosroshahi A, Zhang W, et al.. Inebilizumab for treatment of IgG4-related disease. N Engl J Med. 2025, 392:1168-77. 10.1056\/NEJMoa2409712","journal-title":"N Engl J Med"},{"key":"ref11","unstructured":"Uplizna\u00ae (Inbelilizumab-CDON) is now the first and only FDA-approved treatment for IgG4-related disease. (2025). Accessed. January 10, 2025: https:\/\/www.amgen.com\/newsroom\/press-releases\/2025\/04\/uplizna-inebilizumabcdon-is-now-the-first-and-only-fdaapproved-...."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo M","year":"2017","unstructured":"Ebbo M, Grados A, Samson M, et al.. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One. 2017, 12:e0183844. 10.1371\/journal.pone.0183844","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.02.049","article-title":"Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease","volume":"16","author":"Majumder S","year":"2018","unstructured":"Majumder S, Mohapatra S, Lennon RJ, et al.. Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease. Clin Gastroenterol Hepatol. 2018, 16:1947-53. 10.1016\/j.cgh.2018.02.049","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22058","article-title":"Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study","volume":"66","author":"Ebbo M","year":"2014","unstructured":"Ebbo M, Grados A, Guedj E, et al.. Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study. Arthritis Care Res (Hoboken). 2014, 66:86-96. 10.1002\/acr.22058","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/364901-igg4-related-disease-a-case-series-highlighting-diverse-clinical-manifestations-and-treatment-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:51:12Z","timestamp":1760709072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/364901-igg4-related-disease-a-case-series-highlighting-diverse-clinical-manifestations-and-treatment-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.94790","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}